Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 DAC: Structure, Mechanism, and Research Findings

CJC-1295 DAC Explained: Structure, Mechanism, and Research Findings by Dr. Usman | Jan 19, 2026 | Research The peptide was originally developed by ConjuChem, a Canadian biotechnology company, in the mid-2000s.[2] Initial research efforts centered on exploring

By Recovery & Performance Peptides Editorial Team

CJC-1295 DAC Explained: Structure, Mechanism, and Research Findings

by Dr. Usman | Jan 19, 2026 | Research

The peptide was originally developed by ConjuChem, a Canadian biotechnology company, in the mid-2000s.[2] Initial research efforts centered on exploring its potential to modulate growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels. The compound’s design incorporates a Drug Affinity Complex (DAC), a lysine-linked derivative of N-ε-3-maleimidopropionamide, which enables covalent attachment to plasma proteins such as serum albumin.

Contents:

Mechanism of Action

Clinical Studies Implying Interaction Between Growth Hormones and Thyroid

References

Featured Product

Mechanism of Action

CJC-1295 DAC is postulated to act through the endogenous growth hormone axis, mimicking the activity of endogenous GHRH. The peptide binds to GHRH receptors located on somatotroph cells within the anterior pituitary, initiating cyclic adenosine monophosphate (cAMP)-dependent intracellular signaling cascades. This process may activate protein kinase A (PKA), leading to better-supported transcription of GH-encoding genes and exocytotic release of stored GH vesicles.

Physiologically, GH secretion occurs in pulsatile bursts, governed by the interplay between GHRH and somatostatin (growth hormone-inhibiting hormone). Research suggests that analogs like CJC-1295 DAC may reinforce these pulsatile secretions by amplifying the stimulatory phase while maintaining an endogenous mitigatory rhythm.[3] Furthermore, the peptide’s interaction with plasma proteins via the DAC moiety may create a slow-release depot, allowing for sustained receptor activation without overstimulation.

Studies also suggest that CJC-1295 DAC may function synergistically with ghrelin mimetics (e.g., GHRP-6 or Hexarelin), which act on separate ghrelin receptors to suppress somatostatin and support GHRH-driven GH release. This dual-pathway interaction might potentiate IGF-1 synthesis in hepatic tissues, contributing to downstream anabolic and lipolytic signaling pathways. Collectively, the biochemical design of CJC-1295 DAC, combining receptor-specific activity with plasma protein conjugation, appears to optimize both efficacy and stability within experimental models evaluating GH regulation and metabolic homeostasis.

Scientific Research and Studies

Experimental Findings and Endocrine Activity of CJC-1295 DAC

In 2006, researchers conducted two controlled clinical studies to explore the potential endocrine implications of CJC-1295 DAC. The first involved a single ascending concentration design, while the second examined repeated exposure at a fixed concentration.[4] Across both investigations, exposure to CJC-1295 DAC was associated with a measurable increase in circulating growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels compared to baseline models.

The observed rise in IGF-1 is theorized to result from better-supported GH production, which may bind to hepatic GH receptors, initiating downstream activation of the Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway. This cascade potentially leads to phosphorylation of STAT proteins and their translocation to the nucleus, where they may engage specific DNA response elements to promote IGF-1 gene transcription.

Experimental data suggest that exposure to CJC-1295 DAC may result in 2- to 10-fold elevations in GH persisting for up to six days, while IGF-1 levels may increase 1.5- to 3-fold and remain above baseline for approximately 9-11 days. In repeated-exposure models, these elevations reportedly persisted for up to 28 days, suggesting a possible cumulative implication on the GH-IGF-1 axis, suggesting “the potential [implications] of CJC-1295 as a [helpful] agent.”[4]

Analysis of Mammalian Growth Hormone Pulsatility, Receptor Pathway Activation

A separate 2006 investigation assessed the peptide’s support for GH pulsatility following a single peptide introduction.[5] Findings reported an approximate 50% increase in mean GH secretion and a similar elevation in IGF-1 levels compared to baseline, with peak GH concentrations reported to rise as much as 7.5-fold.

At the molecular level, CJC-1295 DAC is believed to interact with the growth hormone-releasing hormone (GHRH) receptor, a G-protein-coupled receptor located on somatotroph cells in the anterior pituitary. This receptor engagement may activate G-protein subunits, promoting the synthesis of intracellular second messengers such as cyclic adenosine monophosphate (cAMP) and inositol trisphosphate (IP3).

These messengers, in turn, are thought to activate protein kinases, which phosphorylate transcription regulators involved in GH gene expression.[6] This multi-step signaling cascade may therefore support GH synthesis and release, aligning with the peptide’s observed ability to sustain elevated GH output within mammalian research models.

Preclinical Assessment in GHRH-Deficient Murine Models

Further investigations were carried out using murine models lacking the GHRH gene (GHRHKO) to evaluate the anabolic potential of CJC-1295 DAC. In these studies, subjects received either daily or intermittent peptide exposure, while control groups received a placebo. Findings suggest that daily exposure nearly normalized growth profiles in GHRHKO models, while exposure every two to three days produced intermediate implications, suggesting a frequency-dependent response.

CJC-1295 DAC was associated with increased lean muscular tissue mass preservation and reduced fat accumulation, potentially indicating support for mass of mammalian models through GH-mediated anabolic pathways. Additionally, the peptide appeared to increase pituitary total RNA and GH mRNA levels, suggesting a rise in somatotroph cell proliferation.

Immunohistochemical observations have supported this hypothesis, revealing better-supported somatotroph density within the anterior pituitary following peptide exposure. Collectively, these preclinical findings imply that CJC-1295 DAC may modulate GH synthesis, pituitary cellular activity, and tissue growth dynamics through mechanisms consistent with its classification as a long-acting GHRH analog.

Supplementary Investigations and Analytical Evaluations

In 2005, a clinical investigation[8] was initiated to examine the potential endocrine and metabolic activity of CJC-1295 DAC in models representing HIV-associated visceral adiposity. The planned study design involved peptide exposure over three months, followed by a six-week observational phase to monitor post-exposure outcomes. However, this investigation was discontinued during the recruitment phase, and no validated findings or results were reported from the trial.

Subsequently, a 2009 analytical study conducted by researchers from the Norwegian Doping Control Laboratory and the School of Pharmacy aimed to identify the biochemical nature of an unfamiliar compound submitted for substance verification. Analytical characterization reported that the peptide “CJC-1295 DAC is a releasing factor for growth hormone.”[1]

Pharmacokinetic Modifications and Half-Life Extension

CJC-1295 DAC incorporates a molecular engineering platform referred to as the Drug Affinity Complex (DAC), designed to prolong peptide stability through plasma protein binding.[1] Endogenous growth hormone-releasing hormone (GHRH) is characterized by a brief biological half-life of approximately 7 minutes, largely due to rapid enzymatic degradation.

In contrast, CJC-1295 without DAC, also referred to as Modified GRF (1–29), exhibits a longer half-life of about 30 minutes, attributed to targeted amino acid substitutions within its 29-residue fragment. Structural modification of four amino acid positions, 2, 8, 15, and 27, is theorized to support the peptide’s resistance to dipeptidyl peptidase-4 (DPP-IV) degradation and oxidative instability. These substitutions include:

Position 2: L-alanine replaced by D-alanine, potentially supporting enzymatic stability.

Position 8: Asparagine replaced by glutamine, which may reduce susceptibility to deamidation and amide hydrolysis.

Position 15: Glycine replaced by alanine, a substitution hypothesized to support greater receptor binding efficiency.

Position 27: Methionine replaced by leucine, potentially minimizing oxidative reactions and preserving peptide integrity.

The addition of the DAC moiety, formed by conjugation of a lysine residue to N-ε-3-maleimidopropionamide, further extends the circulating half-life through reversible binding to serum albumin. This binding mechanism may create slow-release implications, resulting in a prolonged biological half-life estimated between 6 and 8 days [9] Collectively, these molecular adaptations appear to optimize both pharmacokinetic stability and functional persistence under laboratory conditions.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References:

Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010 Nov-Dec;2(11-12):647-50. doi: 10.1002/dta.233. Epub 2010 Dec 10. PMID: 21204297. https://pubmed.ncbi.nlm.nih.gov/21204297/

Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006. Epub 2006 Jul 5. PMID: 16822960. https://pubmed.ncbi.nlm.nih.gov/16822960/

Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996. https://pubmed.ncbi.nlm.nih.gov/32257855/

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/

Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/

Newton, A. C., Bootman, M. D., & Scott, J. D. (2016). Second Messengers. Cold Spring Harbor perspectives in biology, 8(8), a005926. https://doi.org/10.1101/cshperspect.a005926

ClinicalTrials.gov, A service of the US National Institutes of Health. Available at: http://clinicaltrials.gov/ct2/show/NCT00267527

Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016 Jan 2;51(1):73-84. doi: 10.3109/10826084.2015.1082595. Epub 2016 Jan 15. PMID: 26771670. https://pubmed.ncbi.nlm.nih.gov/26771670/

Dr. Usman

Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.

Latest Post

BPC157: Molecular Characterization, Pleiotropic Signaling Mechanisms, and Preclinical Research

Copper Peptides: Molecular Characterization, Mechanistic Biology, and Emerging Research

Modified GRF 1-29 and GHRP-2 Peptide Blend: Receptor Pharmacology, Somatotroph Signaling, and Neuroendocrine Research

Fragment 176-191, Modified GRF 1-29, and Ipamorelin Blend: Adipose Metabolism, GH Axis Modulation, and Receptor Signaling Research

PNC-27: Structural Characterization, HDM-2-Dependent Membrane Targeting, and Selective Tumor Cell Necrosis

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

PROCEDURE

How to Distinguish Safe Cloudiness from Contamination

There is no such thing as 'safe cloudiness' in reconstituted CJC-1295. Any visible opacity indicates the peptide is no longer usable. The distinction research teams sometimes reference applies only to lyophilized powder before reconstitution: an intact lyophilized cake may have a slightly off-white or beige tint due to excipients like mannitol, but this is not cloudiness. Once mixed with bacteriostatic water, the solution must be perfectly clear. Any deviation from crystal-clear transparency means the vial should be discarded. Some researchers ask whether 'temporary cloudiness' that resolves after gentle swirling is acceptable. The answer is no. True reconstitution creates an immediate, homogenous solution. If the peptide appears cloudy initially and clears after agitation, what you're observing is incomplete dissolution, which suggests the lyophilized cake was compromised before mixing (likely from moisture ingress during storage). Incomplete dissolution leaves undissolved peptide fragments that won't be bioavailable and may cause injection-site reactions. Particulate matter. Tiny visible specks suspended in otherwise clear liquid. Is equally unacceptable. These particles are typically aggregated protein or cellulose fibers from non-sterile handling. Even if the bulk solution appears clear, any particulate matter disqualifies the vial from use. Inject particulates into subcutaneous tissue and you're introducing foreign material that triggers localized immune responses. Infl…
DOSAGE SOURCE

CJC-1295 Dosage Ranges for Tendon Healing Research

Research-grade CJC-1295 tendon healing protocols typically use dosing ranges between 200–300 micrograms (mcg) per injection, administered twice weekly. This dosing frequency aligns with the peptide's 6–8 day half-life while preventing receptor saturation that would reduce response magnitude over time. Single doses above 500 mcg do not produce proportionally greater IGF-1 elevation. The pituitary GH response plateaus due to feedback inhibition from elevated somatostatin, the hormone that counteracts GHRH signaling. The twice-weekly schedule (e.g., Monday evening and Thursday evening) maintains stable plasma CJC-1295 levels without creating the receptor downregulation seen with daily dosing. GHRH receptors exhibit desensitization when continuously occupied, similar to other G-protein coupled receptors. Spacing injections 72–96 hours apart allows receptor resensitization between doses. Studies examining growth hormone secretagogue responsiveness found that subjects dosed every 3–4 days maintained 85–90% of initial GH pulse amplitude after 12 weeks, while daily dosing reduced response amplitude to 40–55% by week 8. Dosing is calculated per kilogram of body weight in many research protocols, with 1–2 mcg/kg being the standard range. A 90 kg individual would dose 90–180 mcg per injection under this calculation, though most studies converge on the 200–300 mcg fixed-dose range regardless of body weight because the pituitary response saturates within this window. Higher doses increas…
02

Question drills

Open a question for its connected answer.

01What If I'm Using CJC-1295 with Ipamorelin During Intermittent Fasting?+

Continue the protocol. Both peptides are fasting-compatible. Ipamorelin enhances the GH pulse from CJC-1295 without stimulating appetite or cortisol, making it one of the most fasting-friendly peptide combinations. Inject during your fasting window or immediately before breaking your fast. Neither peptide contains calories or insulin-stimulating compounds.

SOURCE / realpeptides.co ↗
02What If You Need an Oral Alternative to CJC-1295?+

Choose MK-677. It's the only growth hormone secretagogue with demonstrated oral bioavailability. Administer 25mg once daily; steady-state IGF-1 elevation occurs within 7–10 days and persists without tachyphylaxis for at least 2 years based on published trials. The mechanism: MK-677 survives gastric acid and binds GHSR-1a after hepatic first-pass metabolism, triggering GH release without requiring injection. The caveat: appetite stimulation is unavoidable. Studies show 200–300 calorie/day increases in food intake, which may confound metabolic endpoints unless controlled.

SOURCE / realpeptides.co ↗
03What If I Accidentally Shook the Vial After Reconstitution?+

The current vial's potency is reduced but not eliminated. Continue using it, but expect 20–40% lower efficacy for the remaining doses. Shaking introduces shear forces that break some disulfide bonds in the peptide chain, reducing the percentage of correctly-folded molecules available to bind GHRH receptors. The damage is done and cannot be reversed. For the next vial, reconstitute using the correct technique: bacteriostatic water added down the wall, gentle swirling only, no agitation. Researchers who shake vials consistently report plateau or diminished results by week 3–4 even when all other variables are controlled.

SOURCE / realpeptides.co ↗
04What If the Reconstituted Solution Develops Cloudiness or Particles After a Week in the Fridge?+

Stop using the vial immediately. Cloudiness indicates either bacterial contamination or peptide aggregation. Both render the solution unsuitable for research. Aggregation occurs when improperly stored peptides form insoluble complexes that no longer bind GHRH receptors. Particles may represent bacterial colonies or precipitated peptide fragments. Filter the solution through a 0.22-micron sterile filter if you need to confirm contamination versus aggregation, but in practice, any visible change from the clear colourless state warrants disposal.

SOURCE / realpeptides.co ↗
05What If I Miss a Scheduled CJC-1295 Injection?+

Administer the missed dose as soon as you remember if fewer than 48 hours have passed, then resume your regular schedule. If more than 48 hours have passed, skip the missed dose entirely and continue with the next scheduled injection. Do not double-dose. CJC-1295 DAC has a six-to-eight-day half-life, so missing one injection does not eliminate all circulating peptide, but it does reduce the GH pulse amplitude for that cycle.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Navigating the Research Process: A CJC-1295 Beginners Guide Approach

Embarking on research with peptides like CJC-1295 requires a methodical and responsible approach. It's not just about getting the compound; it's about setting up your study for success and ensuring accurate, reproducible results. First, always source your peptides from a reputable supplier. Honestly, though, this is paramount. At Real Peptides, we stand by our small-batch synthesis and exact amino-acid sequencing, guaranteeing the purity and consistency that your research demands. You can explore our full range knowing that quality is our relentless focus. Next, familiarizing yourself with the specific form of CJC-1295 you're using—with DAC or without—is non-negotiable. This directly impacts your reconstitution, dosing, and administration schedule, which we'll delve into shortly. A solid CJC-1295 beginners guide always emphasizes this foundational knowledge. We've found that many early-stage research challenges stem from a lack of clarity on these fundamental distinctions. Finally, always adhere to strict laboratory protocols. This includes proper handling, storage, and disposal of research compounds. Safety, precision, and ethical considerations should be at the forefront of every step. Our team actively provides resources and guidelines to support responsible research practices, because the integrity of your findings, and indeed the entire scientific community, depends on it. Discover how our rigorous standards ensure optimal results for your experiments, and find the right peptide tools for your lab.

RESEARCH

Research Applications: Where CJC-1295 Shines Brightest

The utility of CJC-1295 extended half-life GH release spans a formidable range of research areas. It's not just a single-purpose compound; its sustained action makes it incredibly versatile. Metabolic Health Studies: Researchers investigating metabolic syndrome, glucose regulation, or lipid metabolism often look to GH pathways. The sustained GH release from CJC-1295 allows for longer-term observation of metabolic markers, offering clearer insights into potential interventions. We've seen significant interest in this area, particularly as global metabolic health challenges grow in 2026. Muscle Growth and Repair: For studies focused on muscle anabolism, sarcopenia, or recovery from injury, the steady, physiological elevation of GH can be incredibly beneficial. It supports protein synthesis and cellular repair mechanisms. Our Muscle Building Research collection provides further context on compounds relevant to this area. Longevity Research: The role of growth hormone in aging processes is a complex but fascinating field. Sustained, physiological GH release, as offered by CJC-1295 extended half-life GH release, provides an excellent tool for researchers exploring its impact on cellular senescence, tissue maintenance, and overall healthy aging. This aligns perfectly with the goals of many studies in Longevity Research. Cognitive Function and Neurological Health: Emerging research suggests GH may play a role in brain health and cognitive function. Peptides like CJC-1295 offer a stable way to study these connections without the sharp fluctuations that shorter-acting compounds might induce. This area of study is gaining traction, and we're seeing more inquiries into its potential. Bone Density and Connective Tissue Studies: GH is known to influence bone mineral density and the health of connective tissues. For long-term studies on osteoporosis models or injury recovery, the consistent support from CJC-1295 extended half-life GH release offers a stable research environment. Each of these applications benefits immensely from the predictable, prolonged action of CJC-1295 extended half-life GH release, allowing for more accurate and less labor-intensive experimental designs.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles